Hagop Kantarjian, M.D rx pills ., Neil P. Shah, M.D., Ph.D., Andreas Hochhaus, M.D., Jorge Cortes, M.D., Sandip Shah, M.D., Manuel Ayala, M.D., Beatriz Moiraghi, M.D., Zhixiang Shen, M.D., Jiri Mayer, M.D., Ricardo Pasquini, M.D., Hirohisa Nakamae, M.D., Ph.D.D.D., Charles Chuah, M.R.C.P., M.D., Eric Bleickardt, M.D., M. Brigid Bradley-Garelik, M.D., Chao Zhu, Ph.D., Ted Szatrowski, M.D., David Shapiro, M.D., and Michele Baccarani, M.D.: Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Chronic myeloid leukemia in the chronic phase, a clonal myeloproliferative disorder, is due to the constitutively active BCR-ABL tyrosine kinase caused by the translocation that produces the Philadelphia chromosome.1,2 Imatinib , an inhibitor of the BCR-ABL kinase, may be the standard first-range therapy for sufferers with chronic-phase CML.3-6 Dasatinib , a second-generation BCR-ABL kinase inhibitor, has been approved while a second-line treatment for patients with CML if imatinib therapy fails.4-7 Dasatinib therapy induces a comprehensive cytogenetic response in approximately 50 percent of patients who do not have a response to imatinib or cannot tolerate it.8-10 Among individuals with newly diagnosed chronic-phase CML who are receiving imatinib, the long-term outcome is even more favorable for those in whom a total cytogenetic response is accomplished at 12 months or earlier than for all those in whom a complete cytogenetic response is not achieved by 12 a few months.
No irregular cardiac rhythm or electrocardiographic changes, including the QT interval corrected for heartrate, were detected. Zero pattern of symptoms suggesting clinical hypothyroidism or thyrotoxicosis was observed. Serum markers of bone turnover, including bone-specific alkaline phosphatase, and type I collagen breakdown product, had been unchanged. An isolated, nonsignificant 3 to 19 percent upsurge in the amount of serum procollagen type I N-terminal propeptide was seen in the highest-dosage group, but a similar idiopathic upsurge in the known degree of PINP has been observed during statin treatment.28 No undesireable effects related to sexual dysfunction were observed, and levels of serum free testosterone in men and estradiol in females were unchanged .